ADARx Pharmaceuticals, Inc. (ADRX)
12.67
-1.49
(-10.52%)
USD |
NASDAQ |
Nov 20, 16:00
ADARx Pharmaceuticals Debt to Equity Ratio : 0.0112 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0112 |
| June 30, 2026 | 0.0647 |
| Date | Value |
|---|---|
| March 31, 2026 | 0.0556 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Korsana Biosciences, Inc. | 0.0031 |
| IRulya Therapeutics, Inc. | 0.00 |
| PepGen Inc. | 0.1514 |
| Q32 Bio, Inc. | 0.0178 |
| Bridgebio Oncology Therapeutics, Inc. | 0.0081 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 929.06M |
| Total Liabilities (Quarterly) | 354.66M |
| Shareholders Equity (Quarterly) | 574.40M |
| Current Ratio | 21.08 |
| Net Debt Paydown Yield | -0.03% |